Allan Gabor Takes Over the Leadership of Merck in China
“I am very happy that Allan Gabor, who has extensive management experience, also in China, will be taking on this important task in one of the most important regional markets for Merck. He has known the sector and the country for two decades and has already achieved important advances in our Healthcare business in China,” said Beckmann, who also praised the accomplishments of Alasdair Jelfs: “I thank him for his many years of service in China.” Jelfs will take over other responsibilities at Merck.
The inclusion of the future head of Merck in China in the Performance Materials Leadership Team underscores the strategic importance of the Chinese market to the business sector. The change is part of a realignment of the entire business sector, which under the leadership of Kai Beckmann has developed a strategy to sharpen its focus on markets and customers. The OLED materials business will be combined with the Liquid Crystals business into a single business unit. In addition, all activities pertaining to research, business development and external partnerships will be united in a central research and innovation unit. Production and Supply Chain activities will also be realigned.
Allan Gabor has been working for Merck since 2013 and serves as the Head of the Biopharma business in Asia, including China. He has more than 25 years of management experience in leadership roles in countries such as China, Turkey, Russia, and the United States. Prior to joining Merck, he was head of Pfizer in China, where he has been working since 1999.
Most read news
Other news from the department people
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.